SUO 2024 Bladder Cancer - Results from #20

Viewing 21-40 of 49 articles

SUO 2024: Utility of Rescue Bacillus Calmette-Guerin Therapy in Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

SUO 2024: Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC: A Single Arm, Open Label, Phase 3B Trial

SUO 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer

SUO 2024: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single Arm, Open Label, Phase 3 Trial (ENVISION)

SUO 2024: Safety and Tolerability of TAR-200 Monotherapy in Patients with BCG-Unresponsive High Risk NMIBC in SunRISE-1

SUO 2024: BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

SUO 2024: UR001: A Phase 1 Dose-Escalation Study of UGN-301 (Zalifrelimab) in Patients with Recurrent Non Muscle Invasive Bladder Cancer

SUO 2024: Low-grade and High-grade Intermediate-risk Non-muscle Invasive Bladder Cancers Respond Differently to Bacillus Calmette-Guerin and Gemcitabine-Docetaxal

SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer

SUO 2024: The Efficacy of Salvage BCG for Recurrent Non-muscle Invasive Bladder Cancer After First-line Gemcitabine and Docetaxel

SUO 2024: Mechanism of Action and Translation to the Clinic of Detalimogene Voraplasmid (EG-70) – A Novel, Investigational Non-Viral Immunotherapy for NMIBC

SUO 2024: Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk BCG-Unresponsive NMIBC with CIS

SUO 2024: Trial Design for BCG Unresponsive NMIBC: Time to Move Past Single Arm Registration Trials?

SUO 2024: Setting the Stage – Overview of Emerging Intravesical Therapy Options: Mechanism of Action, Efficacy, Tolerability, Financial Considerations/Access

SUO 2024: Adjuvant Systemic Therapy in Urothelial Carcinoma: Where Are We At Today?

SUO 2024: Disease-Free Survival and Overall Survival in Patients with High-Risk Muscle-Invasive Bladder Cancer Who Have Persistent Circulating Tumor DNA-Negative Biomarker Status Post-Cystectomy: IMvigor011 Study Surveillance Analysis

SUO 2024: E-cigarette Use and the Risk of Bladder Cancer

SUO 2024: Implementing Smoking Cessation in the Urologic Oncology Setting

SUO 2024: Management of the Bladder in Metastatic Patients Following Complete Response to Systemic Therapy: Is There a Role for Consolidative Local Therapy?

SUO 2024: Adjuvant Radiation Following Cystectomy: Underutilized Therapy?

1
2
3